New Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Azacitidine Demonstrate Robust Responses and a Well Tolerated Safety Profile in Newly Diagnosed IDHm AML Patients

World News: . []

CHICAGO June 04 2018 GLOBE NEWSWIRE -- Agios Pharmaceuticals Inc NASDAQAGIO a leader in the field of cellular metabolism to treat cancer and rare genetic diseases today presented encouraging new data from a Phase 1 study evaluating ivos idenib ...

More news and information about Agios Pharmaceuticals, Inc.

Published By:

Globe Newswire: 14:00 GMT Monday 4th June 2018

Published: .

Search for other references to "data" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us